Downloads

RSS

CSL Limited has been Australia's fractionator of plasma- derived therapeutics under various agreements with Australia's Commonwealth Government since 1954. CSL Bioplasma's unique, state-of-the-art facility in Broadmeadows – which began operations in 1994 – employs chromatography, a method of separating proteins based on their differing size and charge. Chromatography is a gentle way of fractionating proteins, allowing CSL Bioplasma to produce plasma-derived therapeutics of high purity with high recoveries, thus optimizing the yield of every protein of interest from each blood donation. CSL Bioplasma's facility is one of the most sophisticated plasma fractionation plants in the world.

Besides being the chosen plasma fractionator for Australia, CSL Bioplasma has also been selected by the governments and blood services of New Zealand, Singapore, Hong Kong, Malaysia, and Taiwan. The plasma-derived therapeutics that CSL Bioplasma produces for Australia are provided free of charge by Australia's Commonwealth, state, and territory governments for use in Australian hospitals in the treatment of serious medical conditions. These include disorders of the immune system, various serious nerve and muscle diseases, bleeding disorders such as hemophilia, blood loss and blood replacement in trauma and surgery, and hemolytic disease of the newborn.